Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review

Knez, Lea; Sodja, Eva; Kern, Izidor; Košnik, Mitja; Čufer, Tanja

doi:10.1016/j.lungcan.2011.02.014

Cited by 24 publications

(23 citation statements)

References 37 publications

(83 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many biomarkers have been evaluated, for example, multidrug resistance-associated proteins such as multidrug resistance protein 1 (P-glycoprotein; MDR1), multidrug resistance-associated protein1 (MRP1) and 2 (MRP2), major vault protein (MVP), topoisomerases II (topo II) [42], and serum markers such as lactate dehydrogenase (LDH), neuron-specific enolase (NSE) [43]and so on. Nowadays, circulating tumour cells (CTCs) has also emerged as a potential predictive and prognostic factor for SCLC [44].…”

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

Recently, the correlation between the efficacy of platinum-based chemotherapy and ERCC1 expression in patients with SCLC has attracted wide-spread attention, and a lot of investigations have been conducted, whereas conflicting results were presented. Therefore, we performed the present meta-analysis of eligible studies to derive a more precise evaluation of the association between ERCC1 expression and the clinical outcome in SCLC patients receiving platinum-based chemotherapy. A literature search for relevant studies was conducted in the electronic databases of PubMed, EMBASE and Web of Science. The inclusive criteria were SCLC patients treated by platinum-based chemotherapy, and evaluated the relationship between ERCC1 expression and the clinical outcomes [including overall response rate (ORR), overall survival (OS) or progression-free survival (PFS)]. Odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI) was calculated to assess the risk. A total of nine studies including 1129 patients were included in final analysis. Our analysis indicated that positive/high ERCC1 expression was associated with unfavorable OS (HR = 1.18, 95%CI = 1.02–1.37) and PFS (HR = 1.46, 95%CI = 1.14–1.88). Subgroup analysis according to disease stage suggested the significant relationship was found in limited stage (LS-SCLC), but not in extensive stage (ES-SCLC). However, no significant association was found between ERCC1 expression and ORR. Our analysis suggested ERCC1 expression may be a prognostic factor in SCLC patients receiving platinum-based chemotherapy, especially for LS-SCLC.

show abstract

Section: Discussionmentioning

confidence: 99%

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Tumors deficient in cell cycle signaling pathways (Chk2, ATM, p53), DNA repair (XPF, ERCC1, Mre11, Nbs1, CtIP) and/or homologous recombination (CtIP, BRCA1, BRCA2) should be prime candidates for combination chemotherapies with Top1 and Tdp1 inhibitors. Most notable examples might be colon cancers with Mre11 mutations 41, 42 and lung cancers with ERCC1 mutations 25, 43 . It remains to be determined whether BRCA1- or BRCA2-deficient tumors will be selectively sensitized by Tdp1 inhibitors because, in budding yeast, Rad52 is epistatic with Tdp1 16, 20 .…”

Section: Expert Opinionmentioning

confidence: 99%

Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors

Huang

Pommier

Marchand

2011

Expert Opinion on Therapeutic Patents

View full text Add to dashboard Cite

Inhibitors of topoisomerase I (Top1) that result in stalled Top1 cleavage complexes (Top1cc) are commonly employed against cancer. Combination chemotherapy with DNA repair inhibitors can potentially improve response to these widely used chemotherapeutics. One line of inquiry focuses on inhibitors of tyrosyl-DNA phosphodiesterase 1 (Tdp1), a repair enzyme for Top1cc. Tdp1 catalyzes the hydrolysis of DNA adducts covalently linked to the 3′-phosphate of DNA, including Top1-derived peptides and also 3′-phosphoglycolates. Tdp1 inhibitors should synergize not only with Top1-targeting drugs (camptothecins, indenoisoquinolines), but also with bleomycin, topoisomerase II (Top2) inhibitors (etoposide, doxorubicin) and DNA alkylating agents. Here, we summarize the structural-activity relationship obtained from the reported Tdp1 inhibitors. Better understanding of Top1cc repair in vivo coupled with detailed structural studies on Tdp1-inhibitor interaction will be crucial in guiding the rational design of Tdp1 inhibitors.

show abstract

“…The prognosis of SCLC, which has been associated with extent of disease and other factors, is poor, whereas the life expectancy of those with untreated SCLC is ~3.5 months for the limited stage group and 6 weeks for the extensive stage group (4)(5)(6). Although genetic factors have been identified as prognostic factors for SCLC, the underlying mechanism of this cancer remains unknown (7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

A microRNA-related single nucleotide polymorphism of the XPO5 gene is associated with survival of small cell lung cancer patients

Guo

Wang

et al. 2013

Biomedical Reports

View full text Add to dashboard Cite

Abstract. MicroRNA (miRNA)-related single nucleotide polymorphisms (miR-SNPs) in miRNA processing machinery genes affect cancer risk, treatment efficacy and patient prognosis. A miR-SNP of rs11077 located in the 3'UTR of miRNA processing machinery gene XPO5 was examined in small cell lung cancer (SCLC) patients to evaluate its association with cancer survival. A total of 42 patients were enrolled in the present study and genotyped for rs11077 and survival was assessed using the Kaplan-Meier method, as well as univariate and multivariate analyses. The AA genotype of rs11077 was identified for its significant association with better survival time (P=0.023). In addition, rs11077 was found to associate independently with overall survival in SCLC patients by multivariate analysis (relative risk 2.469; 95% CI, 1.088-5.603; P=0.031). The findings of this study suggest that although miR-SNP studies for miRNA processing machinery genes are still at an early age, miR-SNPs have an impact on cancer survival. In conclusion, a miR-SNP in the 3'UTR region of the XPO5 gene was identified as an independent prognostic marker for survival of advanced SCLC patients. IntroductionSmall cell lung cancer (SCLC), commonly classified by the Veterans Administration Lung Cancer Study Group as Limited stage and Extensive stage groups, constitutes ~15% of all lung cancer cases and is strongly associated with cigarette smoking (1-3). The prognosis of SCLC, which has been associated with extent of disease and other factors, is poor, whereas the life expectancy of those with untreated SCLC is ~3.5 months for the limited stage group and 6 weeks for the extensive stage group (4-6). Although genetic factors have been identified as prognostic factors for SCLC, the underlying mechanism of this cancer remains unknown (7-9).MicroRNAs (miRNAs) are RNA molecules that are ~22 nucleotides long and are involved in various biological processes, such as embryonic development, cell differentiation, proliferation, apoptosis, cancer development and insulin secretion (10,11). More than 700 miRNAs have been identified in humans and these miRNAs are responsible for regulating at least 30% of protein-coding gene expressions (12). A growing body of evidence suggests that miRNAs play important roles in a broad range of biological processes, as previously mentioned (9-11). In the miRNA processing, long primary transcripts of miRNAs (pri-miRNAs) are processed in the nucleus by RNase III Drosha and transported to the cytoplasm by the nuclear transport factor exportin-5 (XPO5) and RAN. In the cytoplasm, RNase III Dicer and transactivation-responsive RNA-binding protein (TRBP) mediate the processing of pre-miRNAs in order to release a 21-bp dsRNA. Additionally, the RNA-induced silencing complex (RISC) including GEMIN3 and GEMIN4 selects a single strand as the mature miRNA and guides the mature miRNAs to their target mRNA sites (10,13-16). miRNA-related single nucleotide polymorphisms (miR-SNPs), defined as SNPs in miRNA genes, miRNA binding site and miRNA processing machi...

show abstract

Predictive value of multidrug resistance proteins, topoisomerases II and ERCC1 in small cell lung cancer: A systematic review

Cited by 24 publications

References 37 publications

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

The Prognostic Value of Excision Repair Cross-Complementation Group 1 (ERCC1) in Patients with Small Cell Lung Cancer (SCLC) Receiving Platinum-Based Chemotherapy: Evidence from Meta-Analysis

Tyrosyl-DNA Phosphodiesterase 1 (Tdp1) inhibitors

A microRNA-related single nucleotide polymorphism of the XPO5 gene is associated with survival of small cell lung cancer patients

Contact Info

Product

Resources

About